Merck & Company Inc (MRK)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 365,000 | 4,608,000 | 3,111,000 | 13,030,000 | 14,519,000 | 15,260,000 | 16,579,000 | 14,180,000 | 13,049,000 | 7,197,000 | 5,571,000 | 7,028,000 | 7,068,000 | 11,518,000 | 10,478,000 | 10,146,000 | 9,842,000 | 9,313,000 | 9,362,000 | 8,399,000 |
| Total stockholders’ equity | US$ in thousands | 37,581,000 | 41,246,000 | 38,693,000 | 46,834,000 | 45,991,000 | 44,458,000 | 43,243,000 | 40,883,000 | 38,184,000 | 35,794,000 | 33,294,000 | 26,945,000 | 25,317,000 | 29,186,000 | 27,642,000 | 26,205,000 | 25,907,000 | 26,838,000 | 27,635,000 | 27,539,000 |
| ROE | 0.97% | 11.17% | 8.04% | 27.82% | 31.57% | 34.32% | 38.34% | 34.68% | 34.17% | 20.11% | 16.73% | 26.08% | 27.92% | 39.46% | 37.91% | 38.72% | 37.99% | 34.70% | 33.88% | 30.50% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $365,000K ÷ $37,581,000K
= 0.97%
Merck & Co Inc's return on equity (ROE) has shown fluctuations over the past several quarters. In Q4 2023, the ROE was notably low at 0.97%, representing a significant decline from the previous quarter. This suggests decreased profitability relative to shareholder's equity during this period.
The ROE rebounded in Q3 2023 to 11.17%, indicating an improvement in profitability compared to Q4 2023. However, the ROE experienced a slight dip in Q2 2023 with a reported value of 8.04%.
The highest ROE in recent quarters was observed in Q4 2022 at 31.57%, indicating strong profitability relative to shareholder's equity during that period. This was followed by Q3 2022 and Q2 2022 where the ROE was 34.32% and 38.34% respectively.
Overall, Merck & Co Inc's ROE has displayed variations, with fluctuations seen across different quarters. Further analysis and examination of the company's financial performance and efficiency in utilizing its equity are recommended to gain a deeper understanding of the factors influencing these fluctuations.
Peer comparison
Dec 31, 2023